S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

INmune Bio (INMB) Earnings Date, Estimates & Call Transcripts

$12.92
+0.26 (+2.05%)
(As of 02/23/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

INMB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

INMB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

INMB Earnings Date and Information

INmune Bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off prior year's report dates.

INmune Bio Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/7/2024
Estimated)
------- 
11/1/2023Q3 2023-($0.48)($0.48)($0.48)-$0.04 million
8/7/2023Q2 2023-($0.36)($0.36)($0.36)-$0.05 million
5/3/2023Q1 2023-($0.36)($0.36)($0.36)-$0.04 million
3/2/2023Q4 2022-($0.32)($0.32)($0.32)-$0.10 million
11/2/2022Q3 2022($0.59)($0.43)+$0.16($0.43)-$0.10 million
8/3/2022Q2 2022($0.50)($0.38)+$0.12($0.38)-$0.02 million    
5/5/2022Q1 2022($0.60)($0.39)+$0.21($0.39)-$0.16 million    
3/3/2022Q4 2021($0.56)($0.55)+$0.01($0.55)-$0.16 million    
11/2/2021Q3 2021($0.43)($0.55)($0.12)($0.55)-$0.01 million    
8/3/2021Q2 2021($0.34)($0.44)($0.10)($0.44)--  
5/4/2021Q1 2021($0.27)($0.32)($0.05)($0.32)--  
3/3/2021Q4 2020($0.31)($0.26)+$0.05($0.24)-$0.01 million  












INmune Bio Earnings - Frequently Asked Questions

When is INmune Bio's earnings date?

INmune Bio has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off last year's report dates. Learn more on INMB's earnings history.

How much revenue does INmune Bio generate each year?

INmune Bio (NASDAQ:INMB) has a recorded annual revenue of $370,000.00.

How much profit does INmune Bio generate each year?

INmune Bio (NASDAQ:INMB) has a recorded net income of -$27.30 million. INMB has generated -$1.52 earnings per share over the last four quarters.


More Earnings Resources from MarketBeat

This page (NASDAQ:INMB) was last updated on 2/23/2024 by MarketBeat.com Staff